对PSGL-1免疫检查点的抗体阻塞增强了T细胞对B细胞淋巴瘤的反应
João L Pereira1,2,3, Liliana Arede1, Francisca Ferreira1,2,4
1i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
Leukemia
|October 25, 2024
概括
用抗体向P-选择蛋白糖蛋白连接体-1 (PSGL-1) 增强了T细胞对抗B细胞淋巴瘤的活性. 这种方法有望改善淋巴瘤患者的免疫疗法反应.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
背景情况:
- 大多数淋巴瘤对当前的癌症免疫疗法没有反应,需要新的治疗策略.
- P-选择蛋白糖蛋白连接体-1 (PSGL-1) 是一种新发现的免疫检查点蛋白质,涉及T细胞耗尽.
研究的目的:
- 研究以抗体向PSGL-1作为B细胞淋巴瘤潜在免疫疗法的疗效.
- 评估PSGL-1阻断对T细胞激活和抗淋巴瘤活性的影响.
主要方法:
- 利用全基共同培养系统,通过PSGL-1抗体干预来评估T细胞对淋巴瘤细胞的反应.
- 在体外治疗的原发性淋巴瘤细胞悬浮液,以分析自身T细胞激活.
- 采用A20同源性B细胞淋巴瘤小鼠模型来评估体内抗瘤效应.
- 在Eμ-Myc淋巴瘤模型中评估了抗PSGL-1对CAR T细胞扩张和疗效的影响.
主要成果:
- 在共同培养系统中,PSGL-1抗体治疗增强了T细胞激活和对淋巴瘤细胞的细胞因子产生.
- 在体外治疗增加了淋巴瘤透T细胞的激活.
- 在体内,PSGL-1抗体的管理减缓了瘤的发展,减少了瘤负担,并调节了T细胞透 (增加CD4+/CD8+,降低Treg).
- 抗PSGL-1疗法在侵袭性淋巴瘤模型中改善了CAR T细胞扩张和疾病控制.
结论:
- 阻断PSGL-1抗体有效地增强T细胞介导的抗淋巴瘤活性.
- 向PSGL-1代表了对B细胞淋巴瘤的有希望的新型免疫治疗策略.
更多相关视频
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
1.2K
07:04Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
248
相关概念视频
01:27Tumor Immunotherapy
486
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
486
01:24B Cell Activation and Differentiation
1.6K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.6K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K